Literature DB >> 21459055

Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume.

D H Vu1, R A Koster, J W C Alffenaar, J R B J Brouwers, D R A Uges.   

Abstract

Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of causative bacteria, therapeutic drug monitoring (TDM) of MFX is recommended. Conventional plasma sampling for TDM is facing logistical challenges, especially in limited resource areas, and dried blood spots (DBS) sampling may offer a chance to overcome this problem. The objective of this study was to develop a LC-MS/MS method for determination of MFX in dried blood spots (DBS) that is applicable for TDM. The influence of paper type, the hematocrit (Hct) and the blood volume per spot (V(b)) on the estimated blood volume in a disc (V(est)) was investigated. The extracts of 8mm diameter discs punched out from DBS were analyzed using liquid chromatography tandem mass spectrometry (LC-MS/MS) with cyanoimipramin as internal standard. The method was validated with respect to selectivity, linearity, accuracy, precision, sensitivity, recovery and stability. The effect of Hct and V(b) on LC-MS/MS analytical result was also investigated. The relationship between MFX concentrations in venous and finger prick DBS and those in plasma was clinically explored. V(est) was highly influenced by Hct while the effect of V(b) appeared to be different among paper types. Calibration curves were linear in the range of 0.05-6.00 mg/L with inter-day and intra-day precisions and biases of less than 11.1%. The recovery was 84.5, 85.1 and 92.6% in response to blood concentration of 0.15, 2.50 and 5.00 mg/L, respectively. A matrix effect of less than 11.9% was observed. MFX in DBS was stable for at least 4 weeks at room condition (temperature of 25°C and humidity of 50%). A large range of Hct value produced a significant analytical bias and it can be corrected with resulting DBS size. A good correlation between DBS and plasma concentrations was observed and comparable results between venous DBS and finger prick DBS was attained. This fully validated method is suitable for determination of MFX in dried blood spot and applicable for TDM.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459055     DOI: 10.1016/j.jchromb.2011.03.017

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  26 in total

1.  Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel.

Authors:  Roy Gerona; Anita Wen; David Aguilar; Jamie Shum; Andrew Reckers; Peter Bacchetti; Monica Gandhi; John Metcalfe
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-07-23       Impact factor: 3.205

2.  Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections.

Authors:  Ben Knippenberg; Madhu Page-Sharp; Sam Salman; Ben Clark; John Dyer; Kevin T Batty; Timothy M E Davis; Laurens Manning
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Why dried blood spots are an ideal tool for CYP1A2 phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

5.  Validation and Application of a Dried Blood Spot Ceftriaxone Assay.

Authors:  Madhu Page-Sharp; Troy Nunn; Sam Salman; Brioni R Moore; Kevin T Batty; Timothy M E Davis; Laurens Manning
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

6.  Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.

Authors:  Teresa L Parsons; Mark A Marzinke; Thuy Hoang; Erin Bliven-Sizemore; Marc Weiner; William R Mac Kenzie; Susan E Dorman; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

7.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

8.  Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Authors:  D H Vu; M S Bolhuis; R A Koster; B Greijdanus; W C M de Lange; R van Altena; J R B J Brouwers; D R A Uges; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

9.  Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.

Authors:  Kim C M van der Elst; Lambert F R Span; Kai van Hateren; Karin M Vermeulen; Tjip S van der Werf; Ben Greijdanus; Jos G W Kosterink; Donald R A Uges; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

10.  Determination of efavirenz in human dried blood spots by reversed-phase high-performance liquid chromatography with UV detection.

Authors:  Justin T Hoffman; Steven S Rossi; Rowena Espina-Quinto; Scott Letendre; Edmund V Capparelli
Journal:  Ther Drug Monit       Date:  2013-04       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.